{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:56:14Z","timestamp":1761562574129},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Marfan syndrome is a rare cause of heart failure due to primary or secondary cardiomyopathy. Recently, sacubitril\/valsartan\u2014an angiotensin receptor blocker-neprilysin inhibitor\u2014has been added in clinical practice as a standard therapy for heart failure. To our knowledge, there are no data on sacubitril\/valsartan's effects on cardiovascular outcomes in patients with Marfan syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 24-year-old man was admitted to our Internal Medicine Department due to dyspnea, ascites, and leg swelling. Arterial blood gas analysis revealed severe hypoxemia with respiratory and metabolic alkalosis. Hilar congestion was highlighted on chest x-ray.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Recurrent acute decompensated heart failure with reduced ejection fraction despite optimal medical therapy in Marfan-related cardiomyopathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions and outcomes:<\/jats:title>\n            <jats:p>Sacubitril\/valsartan was added to optimal medical therapy after hemodynamic stabilization allowing progressive clinical, laboratoristic, and echocardiographic improvement. Patient maintained a free survival from heart failure and a good quality of life until 9-month follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Sacubitril\/valsartan should be effective on pathophysiologic mechanisms and cardiovascular outcomes of Marfan syndrome\u2013related cardiovascular complications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000017978","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T06:58:05Z","timestamp":1574665085000},"page":"e17978","source":"Crossref","is-referenced-by-count":4,"title":["Use of sacubitril\/valsartan in Marfan syndrome\u2013related cardiomyopathy"],"prefix":"10.1097","volume":"98","author":[{"given":"Silvia","family":"Spoto","sequence":"first","affiliation":[{"name":"Internal Medicine Department, University Campus Bio-Medico of Rome, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Valeriani","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, University G. D\u2019Annunzio, Chieti"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Locorriere","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, University Campus Bio-Medico of Rome, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina Beretta","family":"Anguissola","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, University Campus Bio-Medico of Rome, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Lauria","family":"Pantano","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, University Campus Bio-Medico of Rome, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Terracciani","sequence":"additional","affiliation":[{"name":"Cardiology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Caterina","family":"Bono","sequence":"additional","affiliation":[{"name":"Cardiology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Costantino","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, University Campus Bio-Medico of Rome, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Ciccozzi","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistic and Molecular Epidemiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Angeletti","sequence":"additional","affiliation":[{"name":"Unit of Clinical Laboratory Science, University Campus Bio-Medico of Rome, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/TACG.S60472","article-title":"Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome","volume":"8","author":"Von Kodolitsch","year":"2015","journal-title":"Appl Clin Genet"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"e10767","DOI":"10.1097\/MD.0000000000010767","article-title":"The phenotypic heterogeneity of patients with Marfan-related disorders and their variant spectrums","volume":"97","author":"Seo","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jmg.2009.072785","article-title":"The revised Ghent nosology for the Marfan syndrome","volume":"47","author":"Loeys","year":"2010","journal-title":"J Med Genet"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ejcts\/ezv073","article-title":"Cardiomyopathy in Marfan syndrome","volume":"49","author":"Hetzer","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ehf2.12251","article-title":"Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study","volume":"5","author":"Norberg","year":"2018","journal-title":"ESC Heart Fail"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ehf2.12258","article-title":"Insights into implementation of sacubitril\/valsartan into clinical practice","volume":"5","author":"Martens","year":"2018","journal-title":"ESC Heart Fail"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1373\/clinchem.2005.051110","article-title":"Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay","volume":"51","author":"Morgenthaler","year":"2005","journal-title":"Clin Chem"},{"key":"R13-20230915","first-page":"108","article-title":"Ejection fraction improvement and reverse remodeling achieved with sacubitril\/valsartan in heart failure with reduced ejection fraction patients","volume":"7","author":"Almufleh","year":"2017","journal-title":"Am J Cardiovasc Dis"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan","volume":"373","author":"Claggett","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-20230915","first-page":"15","article-title":"NT-proBNP and diastolic left ventricular function in patients with Marfan syndrome","volume":"12","author":"Gehle","year":"2016","journal-title":"Int J Cardiol Heart Vasc"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1161\/01.RES.0000117070.86556.9F","article-title":"B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation","volume":"94","author":"Kapoun","year":"2004","journal-title":"Circ Res"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic-root dilation in Marfan's syndrome","volume":"358","author":"Brooke","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:06:56Z","timestamp":1694815616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017978"}},"subtitle":["The first case report"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":18,"journal-issue":{"issue":"47","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017978","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}